Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K. Kurata T, et al. Among authors: hayashi h, hayashi n. Invest New Drugs. 2014 Oct;32(5):946-54. doi: 10.1007/s10637-014-0112-7. Epub 2014 May 31. Invest New Drugs. 2014. PMID: 24875132 Clinical Trial.
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.
Sakamoto K, Matsuki S, Irie S, Uchida N, Hayashi N, Horiuchi M, Ren S. Sakamoto K, et al. Among authors: hayashi n. Clin Pharmacol Drug Dev. 2020 Oct;9(7):833-840. doi: 10.1002/cpdd.775. Epub 2020 Jan 20. Clin Pharmacol Drug Dev. 2020. PMID: 31960624 Free PMC article. Clinical Trial.
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H. Izutsu K, et al. Among authors: hayashi n. Cancer Sci. 2021 Jun;112(6):2405-2415. doi: 10.1111/cas.14886. Epub 2021 May 7. Cancer Sci. 2021. PMID: 33728735 Free PMC article. Clinical Trial.
Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
Gon Y, Nishi K, Sato K, Maes A, Siddiqui S, Hayashi N, Hirata H, Martin UJ, Reisner C. Gon Y, et al. Among authors: hayashi n. Respir Investig. 2021 Jan;59(1):135-144. doi: 10.1016/j.resinv.2020.06.007. Epub 2020 Sep 8. Respir Investig. 2021. PMID: 32917556 Clinical Trial.
Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, Atsumi T, Suematsu E, Hayashi N, Wang L, Tummala R. Takeuchi T, et al. Among authors: hayashi n. Mod Rheumatol. 2020 Jan;30(1):93-100. doi: 10.1080/14397595.2019.1583832. Epub 2019 Mar 25. Mod Rheumatol. 2020. PMID: 30791804 Clinical Trial.
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, Tummala R. Tanaka Y, et al. Among authors: hayashi n. Mod Rheumatol. 2020 Jan;30(1):101-108. doi: 10.1080/14397595.2019.1583833. Epub 2019 Mar 21. Mod Rheumatol. 2020. PMID: 30793642 Clinical Trial.
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P. Ichinose M, et al. Among authors: hayashi n. Int J Chron Obstruct Pulmon Dis. 2019 Dec 23;14:2993-3002. doi: 10.2147/COPD.S220861. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31920296 Free PMC article. Clinical Trial.
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
Takizawa J, Teshima T, Ennishi D, Ichikawa S, Suzuki R, Kojima A, Takahashi Y, Hayashi N, Kawasumi H, Murayama K, Cheung P, Kawata T, Izutsu K. Takizawa J, et al. Among authors: hayashi n. Leuk Lymphoma. 2024 Nov;65(11):1586-1594. doi: 10.1080/10428194.2024.2370436. Epub 2024 Jul 1. Leuk Lymphoma. 2024. PMID: 38952054 Clinical Trial.
3,608 results